The material is employed in a range of Edwards’ surgical and transcatheter valves, including versions of the Inspiris, Mitris ...

For young Indians grappling with aortic valve disease, the Ross procedure offers a lifeline—one that restores vitality ...

Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue technology have significantly ...

Q1 2025 Earnings Call Transcript April 16, 2025 Abbott Laboratories beats earnings expectations. Reported EPS is $1.09, ...

Edwards Lifesciences (NYSE: EW) today announced eight-year data highlighting positive long-term outcomes with its proprietary Resilia tissue.

Wall Street analysts expect Edwards Lifesciences (EW) to post quarterly earnings of $0.60 per share in its upcoming report, which indicates a year-over-year decline of 9.1%. Revenues are expected to ...

This month: shorter recovery after TAVI, Down syndrome CV insights, the benefits of brisker walking, and more.